BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

MIT and Recursion Launch Boltz-2, Open-Source AI Foundation Model for Structure and Binding Affinity Prediction

by Roman Kasianov   •   June 7, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Researchers at MIT’s Jameel Clinic and CSAIL, in collaboration with Recursion and leveraging NVIDIA’s BioHive-2 supercomputer, have released Boltz-2, an open-source biomolecular foundation model designed to simultaneously predict 3D protein structures and their binding affinities.

Boltz-2 extends beyond earlier innovations such as AlphaFold3 and its own predecessor Boltz-1 (released last year) by integrating affinity predictions with dynamic structural modeling—achieving near-physics-based (FEP) accuracy up to 1000 times faster than traditional computational methods.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

From paper: Boltz-2 model architecture diagram.

Boltz-2 was trained on a large dataset combining ~5 million binding affinity measurements, molecular dynamics simulations, and distillation data. It builds on Boltz-1 by adding a new affinity prediction module, GPU-level optimizations, and a technique called Boltz-Steering, which improves the physical realism of predicted structures. The model also supports user control through contact constraints, template guidance, and method-specific alignment.

See also: Foundation Models: Startups, Industry Updates and the Nobel Prize

Unlike models that treat structure and affinity as separate tasks, Boltz-2 predicts both jointly. It matches the accuracy of free energy perturbation (FEP) methods—physics-based simulations commonly used to estimate binding strength—while running over 1000× faster. In CASP16, it ranked first on binding affinity prediction across 140 complexes. It also performs well on DNA–protein, RNA, and antibody–antigen systems, and captures local dynamics more effectively than Boltz-1 when conditioned on MD data.

From paper: Evaluation of the performance of Boltz-2 against existing co-folding models on a diverse set of unseen complexes. Error bars indicate 95% confidence intervals.

Recursion Co-founder and CEO Chris Gibson contextualized Boltz-2 within a broader vision previously shared at JPM in January, in which he outlined Recursion’s ambition to model biology comprehensively, from atomic details to systemic pathways. On the significance of Boltz-2’s release, Gibson stated:

"Most importantly, Boltz-2 is fully open-source for all academic and commercial uses. With this release, we are entering an era where structural biology predictions will no longer be a differentiator nor a barrier—they are broadly accessible to all. This levels the playing field, opening up new opportunities for small startups and academic labs to be competitive with larger institutions as the field builds on open-source methods like Boltz-2.

It also shifts where value is created and differentiated in the drug discovery process. The focus turns to how well you can integrate this ‘protein layer’ with other multiomics data layers to get a complete view of biological systems; how well you can create an iterative cycle of dry-lab predictions and experimental wet-lab validation; how well you can build modular, adaptive, end-to-end platforms that tie everything together. That’s the long game we've been playing at Recursion since day one, and Boltz-2 accelerates that vision for the entire field."

The development of Boltz-2 was led by MIT professors Regina Barzilay and Tommi Jaakkola, with key contributions from researchers Gabriele Corso, Saro Passaro, and Jeremy Wohlwend, alongside a joint team from MIT and Recursion. Corso told Endpoints News he expects AI models of this class to reach experimental-level accuracy in binding affinity prediction within one to two years.

Boltz-2’s full training pipeline, model weights, and code are publicly available under an MIT license, accessible at boltz.bio/boltz2.

Code: https://github.com/jwohlwend/boltz

Recursion Pharmaceuticals
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.